# Biologic and targeted synthetic DMARD safety in inflammatory arthritis: British Society for Rheumatology guideline scope **Authors:** Stephanie F Ling, Joshua L Bennett, Vanessa J Reid, Saad Ahmed, Mostafa Meshaal Ahmad, Sarah Bennett, Marwan Bukhari, Tom Carver, Mary Chatten, Samantha Cooray, Lucy Craig, Cathy Donaghy, James Galloway, Mark Gibson, Rebecca Heaton, Holly Henderson, Nicola Holroyd, Akhila Kavirayani, Alison Kent, Mariam Malik, Andrew Melville, Tanjina Nasrin, Adlan Wafi Ramli, Alan Rawlings, Emily Rose-Parfitt, Luke Sammut, Ethan S Sen, Demisha Vaghela, Angela Vint, Rosemary Waller, Emma L Williams, Taryn Youngstein, Jean Zhang, Sizheng Steven Zhao, Christopher Holroyd, Stephanie F Ling, Stephanie F Ling, Joshua L Bennett, Vanessa J Reid, Saad Ahmed, Mostafa Meshaal Ahmad, Sarah Bennett, Marwan Bukhari, Tom Carver, Mary Chatten, Samantha Cooray, Lucy Craig, Cathy Donaghy, James Galloway, Mark Gibson, Rebecca Heaton, Holly Henderson, Nicola Holroyd, Akhila Kavirayani, Alison Kent, Mariam Malik, Andrew Melville, Tanjina Nasrin, Adlan Wafi Ramli, Alan Rawlings, Emily Rose-Parfitt, Luke Sammut, Ethan S Sen, Demisha Vaghela, Angela Vint, Rosemary Waller, Emma L Williams, Taryn Youngstein, Jean Zhang, Sizheng Steven Zhao, Christopher Holroyd PMC · DOI: 10.1093/rap/rkaf104 · 2025-10-14 ## TL;DR This paper outlines a new guideline for safely using biologic and synthetic drugs to treat inflammatory arthritis in people of all ages. ## Contribution The guideline includes newer drugs like Janus kinase inhibitors and expands to cover children and young people with inflammatory arthritis. ## Key findings - The guideline incorporates newer pharmacotherapies such as Janus kinase inhibitors. - It extends recommendations to include children and young people with inflammatory arthritis. ## Abstract This guideline will provide up-to-date and evidence-based recommendations for the safe use of biologic and targeted synthetic DMARDs in individuals with inflammatory arthritis (IA) across the life course. Important updates from the 2019 iteration of this guideline will include the incorporation of newer pharmacotherapies (such as Janus kinase inhibitors) and an extension of the target clinical population to cover children and young people with IA. The guideline will be updated and produced in accordance with the British Society for Rheumatology protocol for developing clinical guidelines, updated 2023. ## Full-text entities - **Diseases:** IA (MESH:D001168) - **Chemicals:** Janus (-) --- Source: https://tomesphere.com/paper/PMC12517738